Most Clicked BIO SmartBrief Stories

1. $15.7B biotech fund proposed by mayor of London

BIO SmartBrief | Jun 26, 2015

A biotech fund worth $15.7 billion was proposed by London Mayor Boris Johnson to finance drug development projects and encourage the growth of biotech companies in the city. "London is one of the most powerful scientific discovery engines in the world. We hope to harness our role as a global financial center that will bring more lifesaving drugs to market and deliver a huge boost to the economy," Johnson said. Bloomberg (06/25) Genetic Engineering & Biotechnology News (06/25)

2. Alexion wraps up $8.4B purchase of Synageva

BIO SmartBrief | Jun 24, 2015

The purchase of Synageva BioPharma by Alexion Pharmaceuticals has been completed for $8.4 billion. The acquisition will boost Alexion's rare-disease pipeline. European Pharmaceutical Review (U.K.) (06/23) American City Business Journals (06/23)

3. Bristol-Myers Squibb ceases antiviral discovery program

BIO SmartBrief | Jun 29, 2015

Bristol-Myers Squibb has decided to cancel a program that identifies new antiviral drug candidates, including its work on hepatitis B and HIV. The company said products that have reached market and candidates that have reached clinical development, such as the HIV attachment inhibitor BMS-663068 and hepatitis C drug daclatasvir, will not be affected. PharmaTimes (U.K.) (06/25) Reuters (06/25)

4. Celgene, Juno sign $1B collaboration deal

BIO SmartBrief | Jun 30, 2015

Celgene has entered into a 10-year, nearly $1 billion collaboration with Juno Therapeutics to research and develop treatments for cancer and autoimmune diseases, plus therapies targeting immune system cells. Under the terms of agreement, Juno will receive an upfront payment of $150 million plus an additional payment from Celgene for 9.1 million of its shares at $93 apiece. Celgene will get the option to increase its stake in Juno to up to 30%. Juno will develop and market drugs arising from the collaboration in North America, and Celgene will get the remaining worldwide rights. Bloomberg (06/30)

5. Rheumatoid arthritis biosimilar drugs termed equivalent

BIO SmartBrief | Jun 26, 2015

Merck and Samsung Bioepis say they have demonstrated in Phase III trials that their biosimilar drugs for rheumatoid arthritis -- SB4 and SB2 -- are equivalent to Amgen's Enbrel and Johnson & Johnson's Remicade, respectively. Specialty Pharmacy Continuum (06/24)

6. Drugs from Immunovaccine, Incyte to be combined in cancer trial

BIO SmartBrief | Jun 29, 2015

Immunovaccine will collaborate with Incyte in a Phase Ib trial to evaluate the combination of Immunovaccine's T cell-activating immunotherapy DPX-Survivac and Incyte's epacadostat as a treatment for platinum-sensitive ovarian cancer in patients who have an increased risk of disease recurrence. The firms will likely file an investigational new drug application for the study in the U.S. and Canada later this year. Pharmaceutical Business Review Online (06/26)

7. Etubics to collaborate with National Cancer Institute on cancer immunotherapy

BIO SmartBrief | Jun 25, 2015

A cooperative research and development agreement has been formed between Etubics and the National Cancer Institute to further develop technology from Etubics used in the development of cancer immunotherapy candidates. Under the agreement, Etubics will work with NCI researchers to create a multi-targeted cancer immunotherapy. Trials will be conducted by NCI, and the immunotherapy candidates will be supplied by Etubics. Pharmaceutical Business Review Online (06/24)

8. Novartis acquires biotech firm Spinifex

BIO SmartBrief | Jun 30, 2015

Novartis is buying the U.S.-Australian company Spinifex for $200 million, with additional payments linked to designated milestones. The acquisition will allow the Swiss drugmaker to continue clinical trials of the neuropathic pain medication EMA401, which had positive results in patients with post-herpetic neuralgia in midstage trials. Yahoo (06/29)

9. Juno's lymphoma drug application accepted by FDA

BIO SmartBrief | Jun 30, 2015

Juno Therapeutics' investigational new drug application for its immunotherapy JCAR017 as a treatment for non-Hodgkin lymphoma has been accepted by the FDA. An early-stage trial is planned for this year. American City Business Journals (06/29)

10. Seres pulls in $134M from IPO

BIO SmartBrief | Jun 29, 2015

Seres Therapeutics raised nearly $134 million from an initial public offering that sold 7.43 million shares. The Cambridge, Mass.-based firm is developing an oral treatment for Clostridium difficile. Xconomy (06/25)

Sign up for BIO SmartBrief

Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more